TREATMENT OF OSTEOPOROSIS WITH DICLOFENAC SODIUM

双氯芬酸钠治疗骨质疏松症

• 批准号: 3766090
• 负责人: NORMAN H. BELL
• 金额: --
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3766090
• 关键词: antiinflammatory agents; bone metabolism; chemoprevention; female; human subject; human therapy evaluation; osteoporosis; pathologic bone resorption; postmenopause; prostaglandin inhibitors; skeletal disorder chemotherapy

Previous studies suggest prostaglandins (PGE) mediate postmenopausal bone loss: synthesis of PGE2 by cultured neonatal rat calvaria is increased by ovariectomy and is decreased by 17 Beta-estradiol. Studies were conducted to determine in postmenopausal bone loss, reflected by increases in urinary N-telopeptide, a marker for bone resorption, can be prevented by the NSAID Diclofenac Sodium.

以往的研究表明，前列腺素（PGE）介导绝经后骨 损失：培养的新生大鼠颅骨合成PGE 2增加 通过卵巢切除术，并通过17 β-雌二醇降低。 研究是 以确定绝经后骨质流失，反映在 尿N-端肽（骨吸收的标志物）的增加， NSAID双氯芬酸钠预防。